Targa Resources, Inc. (TRGP)
Live price chart, market sentiment, and community perspectives for Targa Resources, Inc. (NYSE: TRGP).
Live price chart, market sentiment, and community perspectives for Targa Resources, Inc. (NYSE: TRGP).
On our desk, TRGP's recent surge to nearly its 52-week high of $305.08 makes everyone talk about locking in gains. With an 85.2% rally over the past year, it has completely crushed broader sector moves. However, the new 20-year ExxonMobil commitment changes the fundamental long-term growth narrative for the Permian Delaware and Midland basins, making near-term profit-taking a tough psychological trade for long-term holders.
As a hedge fund PM reviewing the Q2 prints, the $3.54 EPS beat over the $2.83 consensus was striking, even though top-line revenues of $4.44 billion missed the $4.90 billion consensus due to lower commodity sales. The real story is the operational strength in the Gathering and Processing and Logistics segments, driving adjusted EBITDA up 38% year over year to $1.603 billion.
From a bio-analyst and midstream sector framework, management lifting its 2026 adjusted EBITDA guidance to the high end of the $5.7 billion to $5.9 billion range provides exceptional forward visibility. But analysts need to watch the capital intensity closely: 2026 net growth capex has been bumped up to roughly $5 billion to fund Delaware Basin plants, field infrastructure, and the Bull Run II pipeline.
Watching the 50-day moving average and broker revisions, US Capital Advisors recently boosted their FY2026 EPS estimate to $10.98 while consensus rests near $11.13. Even with minor downward adjustments to Q3 2026 figures down to $2.51, the broader multi-year trajectory shows consistent earnings growth scaling up toward $12.73 by FY2028.
From our risk management perspective, the primary friction point is the expanding execution burden. While the 20-year fee-based agreements with ExxonMobil secure long-term volume visibility through 2046, the concurrent jump in net growth capital requirements to $5 billion introduces execution risk if supply chain or construction bottlenecks materialize across the system.
Explore plasma cleansing, somatic organ swaps, and BCI.